Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 336

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

POSITION STATEMENT: Glucose Intolerance in Polycystic Ovary Syndrome—A Position Statement of the Androgen Excess Society

Salley, Kelsey E. S., Wickham, Edmond P., Cheang, Kai I., Essah, Paulina A., Karjane, Nicole W., Nestler, John E.·2007·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2007-1549
Open this paper in CoChat — free account

Abstract

OBJECTIVES: Women with polycystic ovarian syndrome (PCOS) are at increased risk for developing glucose intolerance and type 2 diabetes mellitus (DM). Recommendations for the timing and method of screening have varied. The purpose of this statement is to determine the optimal screening method, timing of screening, and treatment modalities for impaired glucose tolerance (IGT) among women with PCOS. PARTICIPANTS: The expert panel was appointed by the Androgen Excess Society (AES) to review the literature and make recommendations based on the available evidence. Meetings were open, and there was no funding for the panel. EVIDENCE: A systematic review was conducted of the published, peer-reviewed medical literature using MEDLINE to identify studies that addressed the prevalence, risk factors, testing, and treatment for IGT in both adults and adolescents with PCOS. Unpublished data were not considered. CONSENSUS PROCESS: The panel held meetings to review the literature and draft the statement as a committee. The AES board members reviewed and critiqued the manuscript, and changes were made based on their comments. CONCLUSIONS: The panel recommends that all patients with PCOS be screened for IGT with a 2-h oral glucose tolerance test. A few members of the AES board recommend alternatively screening women with PCOS for IGT and type 2 DM using an oral glucose tolerance test only in patients with a body mass index of 30 kg/m2 or greater or in lean patients with additional risk factors. Patients with normal glucose tolerance should be rescreened at least once every 2 yr, or more frequently if additional risk factors are identified. Those with IGT should be screened annually for development of type 2 DM. PCOS patients with IGT should be treated with intensive lifestyle modification and weight loss and considered for treatment with insulin-sensitizing agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2007-1549

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 60

  1. Azziz, 2004, The prevalence and features of the polycystic ovary syndrome in an unselected population., J Clin Endocrinol Metab, 89, 2745, 10.1210/jc.2003-032046 · DOI · Paper page
  2. Diamanti-Kandarakis, 1999, A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile., J Clin Endocrinol Metab, 84, 4006, 10.1210/jcem.84.11.6148 · DOI · Paper page
  3. Asuncion, 2000, A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain., J Clin Endocrinol Metab, 85, 2434
  4. Knochenhauer, 1998, Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study., J Clin Endocrinol Metab, 83, 3078
  5. Azziz, Androgen Excess Society 2006 Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline., J Clin Endocrinol Metab, 91, 4237, 10.1210/jc.2006-0178 · DOI · Paper page
  6. Dunaif, 1989, Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome., Diabetes, 38, 1165, 10.2337/diab.38.9.1165 · DOI · Paper page
  7. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)., Hum Reprod, 19, 41, 10.1093/humrep/deh098 · DOI · Paper page
  8. Centers for Disease Control and Prevention (CDC), 2003, Prevalence of diabetes and impaired fasting glucose in adults–United States, 1999–2000., MMWR Morb Mortal Wkly Rep, 52, 833
  9. Chen, 2006, Abnormal glucose tolerance in Chinese women with polycystic ovary syndrome., Hum Reprod, 21, 2027, 10.1093/humrep/del142 · DOI
  10. Weerakiet, 2001, Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome., Int J Gynaecol Obstet, 75, 177, 10.1016/S0020-7292(01)00477-5 · DOI
  11. Kinoshita, 1990, Impaired glucose tolerance in patients with polycystic ovary syndrome (PCOS), Horm Res, 33, 18, 10.1159/000181560 · DOI
  12. Kurioka, 2007, Glucose intolerance in Japanese patients with polycystic ovary syndrome., Arch Gynecol Obstet, 275, 169, 10.1007/s00404-006-0241-0 · DOI
  13. Norman, 1995, Ethnic differences in insulin and glucose response to glucose between white and Indian women with polycystic ovary syndrome., Fertil Steril, 63, 58, 10.1016/S0015-0282(16)57297-5 · DOI
  14. Legro, 2005, Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study., J Clin Endocrinol Metab, 90, 3236, 10.1210/jc.2004-1843 · DOI · Paper page
  15. Anttila, 1998, Polycystic ovaries in women with gestational diabetes., Obstet Gynecol, 92, 13, 10.1016/S0029-7844(98)00133-1 · DOI
  16. Holte, 1998, High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus., J Clin Endocrinol Metab, 83, 1143, 10.1210/jcem.83.4.4707 · DOI
  17. Dunaif, 1992, Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome., Diabetes, 41, 1257, 10.2337/diab.41.10.1257 · DOI
  18. Ek, 1997, Impaired adipocyte lipolysis in nonobese women with the polycystic ovary syndrome: a possible link to insulin resistance?, J Clin Endocrinol Metab, 82, 1147
  19. Ek, 2002, A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance., Diabetes, 51, 484, 10.2337/diabetes.51.2.484 · DOI
  20. Rosenbaum, 1993, Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes, Am J Physiol, 264, E197
  21. Baillargeon, 2004, Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome., J Clin Endocrinol Metab, 89, 242, 10.1210/jc.2003-030437 · DOI
  22. Baillargeon, 2006, Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome., Diabetes Care, 29, 300, 10.2337/diacare.29.02.06.dc05-1070 · DOI
  23. Dunaif, 1996, β-Cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome., J Clin Endocrinol Metab, 81, 942
  24. Ehrmann, 2000, Glucose intolerance in the polycystic ovary syndrome: role of the pancreatic β-cell, J Pediatr Endocrinol Metab, 13, 1299
  25. Goodarzi, 2005, β-Cell function: a key pathological determinant in polycystic ovary syndrome., J Clin Endocrinol Metab, 90, 310, 10.1210/jc.2004-1006 · DOI
  26. Arslanian, 2001, Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and β-cell dysfunction and risk of cardiovascular disease., J Clin Endocrinol Metab, 86, 66
  27. Ehrmann, 2005, Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome., J Clin Endocrinol Metab, 90, 66, 10.1210/jc.2004-0229 · DOI
  28. Trolle, 2005, Risk factors for glucose intolerance in Danish women with polycystic ovary syndrome., Acta Obstet Gynecol Scand, 84, 1192, 10.1111/j.0001-6349.2005.00627.x · DOI
  29. Koivunen, 2001, Metabolic and steroidogenic alterations related to increased frequency of polycystic ovaries in women with a history of gestational diabetes., J Clin Endocrinol Metab, 86, 2591
  30. Mohlig, 2006, Predicting impaired glucose metabolism in women with polycystic ovary syndrome by decision tree modelling., Diabetologia, 49, 2572, 10.1007/s00125-006-0395-0 · DOI
  31. Legro, 2004, Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls., Obstet Gynecol Surv, 59, 141, 10.1097/01.OGX.0000109523.25076.E2 · DOI · Paper page
  32. Kaneko, 1998, A low carbohydrate intake before oral glucose-tolerance tests, Lancet, 352, 289, 10.1016/S0140-6736(05)60263-2 · DOI
  33. 1998, Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group., BMJ, 317, 371, 10.1136/bmj.317.7155.371 · DOI
  34. 1997, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus., Diabetes Care, 20, 1183, 10.2337/diacare.20.7.1183 · DOI · Paper page
  35. Gabir, 2000, The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes., Diabetes Care, 23, 1108, 10.2337/diacare.23.8.1108 · DOI · Paper page
  36. Soderberg, 2004, High incidence of type 2 diabetes and increasing conversion rates from impaired fasting glucose and impaired glucose tolerance to diabetes in Mauritius., J Intern Med, 256, 37, 10.1111/j.1365-2796.2004.01336.x · DOI
  37. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001, Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)., JAMA, 285, 2486, 10.1001/jama.285.19.2486 · DOI · Paper page
  38. Moghetti, 2000, Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation., J Clin Endocrinol Metab, 85, 139
  39. Pan, 1997, Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study., Diabetes Care, 20, 537, 10.2337/diacare.20.4.537 · DOI · Paper page
  40. Wein, 1999, A trial of simple versus intensified dietary modification for prevention of progression to diabetes mellitus in women with impaired glucose tolerance., Aust N Z J Obstet Gynaecol, 39, 162, 10.1111/j.1479-828X.1999.tb03363.x · DOI
  41. Wing, 1998, Lifestyle intervention in overweight individuals with a family history of diabetes., Diabetes Care, 21, 350, 10.2337/diacare.21.3.350 · DOI · Paper page
  42. Durbin, 2004, Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance., Diabetes Obes Metab, 6, 280, 10.1111/j.1462-8902.2004.0348.x · DOI
  43. Gerstein, 2006, Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial., Lancet, 368, 1096, 10.1016/S0140-6736(06)69420-8 · DOI · Paper page
  44. Chiasson, 2002, Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial., Lancet, 359, 2072, 10.1016/S0140-6736(02)08905-5 · DOI · Paper page
  45. Heymsfield, 2000, Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults., Arch Intern Med, 160, 1321, 10.1001/archinte.160.9.1321 · DOI · Paper page
  46. Torgerson, 2004, XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients., Diabetes Care, 27, 155, 10.2337/diacare.27.1.155 · DOI · Paper page
  47. Diabetes Prevention Program Research Group, 2003, Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program., Diabetes Care, 26, 977, 10.2337/diacare.26.4.977 · DOI · Paper page
  48. Knowler, Diabetes Prevention Program Research Group 2005 Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program., Diabetes, 54, 1150
  49. Unluhizarci, 1999, The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome., Clin Endocrinol (Oxf), 51, 231, 10.1046/j.1365-2265.1999.00786.x · DOI
  50. Dereli, 2005, Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease., Endocr J, 52, 299, 10.1507/endocrj.52.299 · DOI
  51. Sharma, 2006, Prevention of diabetes and cardiovascular disease in women with PCOS: treatment with insulin sensitizers., Best Pract Res Clin Endocrinol Metab, 20, 245, 10.1016/j.beem.2006.02.003 · DOI
  52. Bridger, 2006, Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome., Arch Pediatr Adolesc Med, 160, 241, 10.1001/archpedi.160.3.241 · DOI · Paper page
  53. Ibanez, 2000, Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide., J Clin Endocrinol Metab, 85, 3251
  54. Silfen, 2003, Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents., J Clin Endocrinol Metab, 88, 4682, 10.1210/jc.2003-030617 · DOI · Paper page
  55. Saad, 2005, Progression from normal glucose tolerance to type 2 diabetes in a young girl: longitudinal changes in insulin sensitivity and secretion assessed by the clamp technique and surrogate estimates., Pediatr Diabetes, 6, 95, 10.1111/j.1399-543X.2005.00097.x · DOI
  56. Vrbikova, 2007, Prevalence of insulin resistance and prediction of glucose intolerance and type 2 diabetes mellitus in women with polycystic ovary syndrome., Clin Chem Lab Med, 45, 639, 10.1515/CCLM.2007.113 · DOI
  57. American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee, 2005, American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome., Endocr Pract, 11, 126
  58. American College of Obstetricians and Gynecologists, 2002, ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists: number 41, December 2002., Obstet Gynecol, 100, 1389
  59. American Diabetes Association, 2007, Standards of medical care in diabetes–2007, Diabetes Care, 30, S4, 10.2337/dc07-S004 · DOI · Paper page
  60. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome., Fertil Steril, 81, 19, 10.1016/j.fertnstert.2003.10.004 · DOI · Paper page

Cited by

Metadata

Authors
Salley, K. E. S., Wickham, E. P., Cheang, K. I., Essah, P. A., Karjane, N. W., & Nestler, J. E.
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2007-12-01
Volume
92
Issue
12
Pages
4546-4556
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2007-1549
OpenAlex
W2093049350
Cited by
336
References
16
FWCI
24.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.